Health AI Central
Peer-Reviewed Publication
Appl Immunohistochem Mol Morphol2026August 17, 2026Journal Article

Inter-Rater Agreement in PD-L1 (22C3) Expression Evaluation in Colon Cancer.

Dea N M Jepsen1,2, Marianne B Jensen1, Trine L Grantzau3, Astrid L B Bennedsen2, Thomas T Eriksen4, Michael Bzorek1, Ismail Gögenur2,5, Anne-Marie K Fiehn1,5
1Department of Pathology, Zealand University Hospital, Roskilde.
2Center for Surgical Science, Department of Surgery, Zealand University Hospital, Køge.
3Department of Pathology, Rigshospitalet, Copenhagen.
4Visiopharm A/S, Hoersholm.
5Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
PubMed DOI

Abstract

Programmed death-ligand 1 (PD-L1) is a predictive biomarker in various cancers. In colorectal cancer, PD-L1 expression evaluation is not part of the routine examination and standardized evaluation methods are lacking. This study aimed to examine inter-rater agreement in PD-L1 expression evaluation in patients with colon cancer (CC) using different manual scoring methods, and to compare the manual…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.